117 related articles for article (PubMed ID: 31374941)
1. Microbicides and HIV: A Review and an update.
Naswa S; Marfatia YS; Prasad TL
Indian J Sex Transm Dis AIDS; 2012 Jul; 33(2):81-90. PubMed ID: 23188931
[TBL] [Abstract][Full Text] [Related]
2. Microbicides for Topical HIV Immunoprophylaxis: Current Status and Future Prospects.
Zhernov YV; Petrova VO; Simanduyev MY; Shcherbakov DV; Polibin RV; Mitrokhin OV; Basov AA; Zabroda NN; Vysochanskaya SO; Al-Khaleefa E; Pashayeva KR; Feyziyeva NY
Pharmaceuticals (Basel); 2024 May; 17(6):. PubMed ID: 38931337
[TBL] [Abstract][Full Text] [Related]
3. Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.
Gallay PA; Chatterji U; Kirchhoff A; Gandarilla A; Pyles RB; Baum MM; Moss JA
Open Virol J; 2018; 12():1-13. PubMed ID: 29541273
[TBL] [Abstract][Full Text] [Related]
4. History of Rectal Product Use and Country of Residence Influence Preference for Rectal Microbicide Dosage Forms Among Young Sexual and Gender Minorities: A Multi-country Trial Comparing Placebo Douche, Suppository, and Insert Products.
Giguere R; Balán IC; Kutner BA; Choi SK; Tingler R; Johnson S; Macagna N; Webster J; Liu A; Chariyalertsak S; Hoesley C; Gonzales P; Ho K; Kayange N; Palanee-Phillips T; Brown E; Zemanek J; Jacobson CE; Doncel GF; Piper J; Bauermeister JA;
AIDS Behav; 2024 May; ():. PubMed ID: 38740628
[TBL] [Abstract][Full Text] [Related]
5. A conjoint experiment of three placebo rectal products used with receptive anal sex: results from MTN-035.
Bauermeister J; Lin W; Tingler R; Liu A; Chariyalertsak S; Hoesley C; Gonzales P; Ho K; Kayange N; Phillips TP; Johnson S; Brown E; Zemanek J; Jacobson CE; Doncel GF; Piper J;
J Int AIDS Soc; 2024 Mar; 27(3):e26219. PubMed ID: 38494656
[TBL] [Abstract][Full Text] [Related]
6. Strategic actions to advance multipurpose prevention technologies in low- and middle-income countries.
Young Holt B; van der Straten A; Barker T; Chirenje ZM; Cameron AI; Scott C; Casas CP; Romano J
Front Reprod Health; 2023; 5():1150857. PubMed ID: 37465533
[TBL] [Abstract][Full Text] [Related]
7. A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
Thurman AR; Ouattara LA; Yousefieh N; Anderson PL; Bushman LR; Fang X; Hanif H; Clark M; Singh O; Doncel GF
Front Cell Infect Microbiol; 2023; 13():1130101. PubMed ID: 37153145
[TBL] [Abstract][Full Text] [Related]
8. Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
Karim QA; Archary D; Barré-Sinoussi F; Broliden K; Cabrera C; Chiodi F; Fidler SJ; Gengiah TN; Herrera C; Kharsany ABM; Liebenberg LJP; Mahomed S; Menu E; Moog C; Scarlatti G; Seddiki N; Sivro A; Cavarelli M
Front Immunol; 2022; 13():1055042. PubMed ID: 36561760
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches.
Paredes AJ; Volpe-Zanutto F; Vora LK; Tekko IA; Permana AD; Picco CJ; McCarthy HO; Donnelly RF
Mater Today Bio; 2022 Jan; 13():100217. PubMed ID: 35243292
[TBL] [Abstract][Full Text] [Related]
10. Application of Sol-Gels for Treatment of Gynaecological Conditions-Physiological Perspectives and Emerging Concepts in Intravaginal Drug Delivery.
Thapa R; Gurung S; Parat MO; Parekh HS; Pandey P
Gels; 2022 Feb; 8(2):. PubMed ID: 35200479
[TBL] [Abstract][Full Text] [Related]
11. Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap.
Joseph Davey DL; Bekker LG; Bukusi EA; Chi BH; Delany-Moretlwe S; Goga A; Lyerly AD; Mgodi NM; Mugo N; Myer L; Noguchi LM; Stranix-Chibanda L; Slack C; Pintye J
Lancet HIV; 2022 Mar; 9(3):e214-e222. PubMed ID: 35090604
[TBL] [Abstract][Full Text] [Related]
12. Multipurpose Prevention Technologies: Oral, Parenteral, and Vaginal Dosage Forms for Prevention of HIV/STIs and Unplanned Pregnancy.
Young IC; Benhabbour SR
Polymers (Basel); 2021 Jul; 13(15):. PubMed ID: 34372059
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo.
Crakes KR; Herrera C; Morgan JL; Olstad K; Hessell AJ; Ziprin P; LiWang PJ; Dandekar S
J Int AIDS Soc; 2020 Oct; 23(10):e25628. PubMed ID: 33073530
[TBL] [Abstract][Full Text] [Related]
14. Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates.
Lengauer H; Makuc D; Šterk D; Perdih F; Pichler A; Trdan Lušin T; Plavec J; Časar Z
Pharmaceutics; 2020 Apr; 12(4):. PubMed ID: 32290280
[TBL] [Abstract][Full Text] [Related]
15. Topical Inserts: A Versatile Delivery Form for HIV Prevention.
Peet MM; Agrahari V; Anderson SM; Hanif H; Singh ON; Thurman AR; Doncel GF; Clark MR
Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31374941
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention.
Peet MM; Agrahari V; Clark MR; Doncel GF
Pharmaceutics; 2024 Mar; 16(3):. PubMed ID: 38543242
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
